BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), today announced that the first patient has been dosed in a Phase I/II clinical trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancer.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Canadian Intellectual Property Office granted the Company a key patent for its previously submitted application (CA 2984736) “Nasal Formulations of Metoclopramide.”

ABVC Biopharma, Inc. announced that the Zacks Small-Cap Research report dated June 7, 2022 values ABVC at $9.50 per share based upon a financial projection and a series of assumptions in the update.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces its partnership with China-based Hande Sciences (“Hande”) to conduct manufacturing scale-up activities to support the Company’s IND-enabling good laboratory practice (GLP) studies for its lead therapeutic program, QN-302.

Langley Health Services (LHS), a large Central Florida healthcare provider with four locations, has cut charting time in half and increased patient visits since engaging with real-time remote medical scribes from ScribeEMR.

Fact.MR, a market research and competitive intelligence provider: The cardiac resynchronization therapy industry revenues were valued at US$ 5.7 Bn in 2021 and have been predicted to grow at a CAGR of 7.9% from 2022-2032.

Fact.MR, a market research and competitive intelligence provider: The global biotechnology and pharmaceutical services outsourcing market is anticipated to hold a market value of US$ 70 Bn in 2022 and US$ 112.31 Bn by 2032.

Wilmington, Delaware, United States, Transparency Market Research Inc.: 3D printed drugs are medicines that are designed using 3D printing technology to customize them for patients in safe and effective manner.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global interferon market is expected to witness strong growth during the forecast period between 2021 and 2031.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT).